Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02480894 · ClinicalTrials.gov registry record · Phase 1
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT02480894 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 112 participants.
The verdict
NCT02480894, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The purpose of this assessment is to estimate the effect of maraviroc on the PK of BMS-626529 when coadministered in healthy subjects. For the effect of BMS-663068 on the PK of maraviroc, the hypothesis to be statistically tested is that BMS-663068 will not have a clinically significant effect on the PK of maraviroc when coadministered in healthy subjects.
Interventions
- DRUG Maraviroc
- DRUG BMS-663068
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2015-07-07 |
| Est. Completion | 2015-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02480894
The ClinicalTrials.gov registry entry for NCT02480894 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Maraviroc is the first listed.
NCT02480894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02480894 about?
NCT02480894 is a clinical study titled "A Open-label, Drug-Drug Interaction With Maraviroc (DDI)". This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The purpose of this asses...
What is the current status of trial NCT02480894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2015-07-07. Estimated completion is 2015-09-21.
What interventions are being tested in trial NCT02480894?
The interventions under investigation include: Maraviroc (DRUG), BMS-663068 (DRUG).
Who is sponsoring clinical trial NCT02480894?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.